Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Chemomab Therapeutics Ltd 주요 수익원은 High-speed Internet Service from Satellites이며, 최신 수익 발표에서 수익은 25,846입니다. 지역별로는 United States이 Chemomab Therapeutics Ltd의 주요 시장이며, 수익은 25,846입니다.
Chemomab Therapeutics Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Chemomab Therapeutics Ltd의 순손실은 $-8입니다.